Patent · US Active

CGRP receptor antagonists

US8314117B2 · kind B2 · utility

14Cited by

1References

18Claims

0Family size

Assignee

Bristol-Myers Squibb Company · US

Inventors

Guanglin Luo · Newtown, US
Gene M. Dubowchik · Middlefield, US
John E. Macor · Guilford, US

Key dates

Filing date	Oct 12, 2010
Grant date	Nov 20, 2012
Priority date	—
Expiry date	Feb 22, 2031

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D471/20
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The disclosure generally relates to the novel compounds of formula I, including pharmaceutically acceptable salts, which are CGRP receptor antagonists. The disclosure also relates to pharmaceutical compositions and methods for using the compounds in the treatment of CGRP related disorders including migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases such as asthma, and chronic obstructive pulmonary disease (COPD).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.